Age and frailty in COVID-19 vaccine development

Melissa K. Andrew; Janet E. McElhaney

doi:10.1016/S0140-6736(20)32481-8

Age and frailty in COVID-19 vaccine development

Melissa K. Andrew, Janet E. McElhaney

Medicine

Producción científica: Contribución a una revista › Comentario/debate › revisión exhaustiva

42 Citas (Scopus)

Idioma original	English
Páginas (desde-hasta)	1942-1944
Número de páginas	3
Publicación	The Lancet
Volumen	396
N.º	10267
DOI	https://doi.org/10.1016/S0140-6736(20)32481-8
Estado	Published - dic. 19 2020

Nota bibliográfica

Funding Information:
MKA reports grants from the Canadian Frailty Network, Sanofi, Pfizer, and GlaxoSmithKline, personal fees from Pfizer for advisory board membership, and personal fees from Sanofi for advisory board membership and consulting about severe outcomes of influenza in older adults. MKA reports agreement to future payments for serving as a member of the data safety monitoring board for a COVID-19 vaccine trial funded by ImmunoVaccine Technologies. JEM reports personal fees from RestorBio and Sanofi for advisory board membership, GlaxoSmithKline and Merck for data safety monitoring board memberships related to vaccine development outside of COVID-19, and personal fees for serving on the Scientific Advisory Board for an influenza vaccine trial sponsored by Medicago.

ASJC Scopus Subject Areas

General Medicine

PubMed: MeSH publication types

Journal Article
Comment

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/S0140-6736(20)32481-8

Otros archivos y enlaces

Citar esto

@article{9bb5bbddc06d44cc952fa6a2c1b7f324,

title = "Age and frailty in COVID-19 vaccine development",

author = "Andrew, {Melissa K.} and McElhaney, {Janet E.}",

note = "Funding Information: MKA reports grants from the Canadian Frailty Network, Sanofi, Pfizer, and GlaxoSmithKline, personal fees from Pfizer for advisory board membership, and personal fees from Sanofi for advisory board membership and consulting about severe outcomes of influenza in older adults. MKA reports agreement to future payments for serving as a member of the data safety monitoring board for a COVID-19 vaccine trial funded by ImmunoVaccine Technologies. JEM reports personal fees from RestorBio and Sanofi for advisory board membership, GlaxoSmithKline and Merck for data safety monitoring board memberships related to vaccine development outside of COVID-19, and personal fees for serving on the Scientific Advisory Board for an influenza vaccine trial sponsored by Medicago.",

year = "2020",

month = dec,

day = "19",

doi = "10.1016/S0140-6736(20)32481-8",

language = "English",

volume = "396",

pages = "1942--1944",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10267",

}

TY - JOUR

T1 - Age and frailty in COVID-19 vaccine development

AU - Andrew, Melissa K.

AU - McElhaney, Janet E.

N1 - Funding Information: MKA reports grants from the Canadian Frailty Network, Sanofi, Pfizer, and GlaxoSmithKline, personal fees from Pfizer for advisory board membership, and personal fees from Sanofi for advisory board membership and consulting about severe outcomes of influenza in older adults. MKA reports agreement to future payments for serving as a member of the data safety monitoring board for a COVID-19 vaccine trial funded by ImmunoVaccine Technologies. JEM reports personal fees from RestorBio and Sanofi for advisory board membership, GlaxoSmithKline and Merck for data safety monitoring board memberships related to vaccine development outside of COVID-19, and personal fees for serving on the Scientific Advisory Board for an influenza vaccine trial sponsored by Medicago.

PY - 2020/12/19

Y1 - 2020/12/19

UR - http://www.scopus.com/inward/record.url?scp=85097244714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097244714&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(20)32481-8

DO - 10.1016/S0140-6736(20)32481-8

M3 - Comment/debate

C2 - 33220853

AN - SCOPUS:85097244714

SN - 0140-6736

VL - 396

SP - 1942

EP - 1944

JO - The Lancet

JF - The Lancet

IS - 10267

ER -